Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06469307 · ClinicalTrials.gov registry record · NA

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

A NA study of Leukemia and Blood Cancer, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06469307 is a NA study of Leukemia and Blood Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06469307, a NA study of Leukemia and Blood Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.

Conditions Studied

Interventions

  • OTHER DIVERSE Review Process

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-12-09
Est. Completion 2027-06-30
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT06469307

The ClinicalTrials.gov registry entry for NCT06469307 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (92% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which DIVERSE Review Process is the first listed.

NCT06469307 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06469307 about?

NCT06469307 is a clinical study titled "Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)". The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.

What is the current status of trial NCT06469307?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-12-09. Estimated completion is 2027-06-30.

What conditions does trial NCT06469307 study?

This clinical trial studies the following conditions: Leukemia, Blood Cancer.

What interventions are being tested in trial NCT06469307?

The interventions under investigation include: DIVERSE Review Process (OTHER).

Who is sponsoring clinical trial NCT06469307?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06469307 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.